Alfi Yasmina

Dr. Alfi Yasmina

Lambung Mangkurat University
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2018 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
AIAndras Inotai
Andras Inotai
DBDiana city Brixner
Diana city Brixner
NMNikos Maniadakis
Nikos Maniadakis
IDIwan Dwiprahasto
Iwan Dwiprahasto
EKErna Kristin
Erna Kristin
ZKZoltán Kaló
Zoltán Kaló
Off-patent pharmaceuticals (OPPs) hold vital importance in meeting public health objectives, especially in developing countries where resources are limited. OPPs are comprised of off-patent originals, branded generics and unbranded generics; nonetheless, these products are not identical and often there are differences in their equivalence, manufacturing quality standards and reliability of supply. This necessitates reconsideration of the lowest price policy objective in pharmaceutical decision making. The aim of this study was to develop a Multi-Criteria Decision Analysis (MCDA) framework through a pilot workshop to inform the national procurement of OPPs in Indonesia. An initial list of potentially relevant criteria was identified based on previous work and a literature review. In a 2-day pilot policy workshop, twenty local experts representing different stakeholder groups and decision-making bodies selected the final criteria, approved the scoring function for each criterion, and assigned weights to each criterion. An MCDA framework was proposed for OPP drug decision making in developing countries, which included price and 8 non-price criteria. Based on the pilot policy workshop 6 + 1 criteria were considered relevant for Indonesia: pharmaceutical price (40% weight), manufacturing quality (18.8%), equivalence with the reference product (12.2%), product stability and drug formulation (12.2%), reliability of drug supply (8.4%), real world clinical or economic outcomes, such as adherence or non-drug costs (4.2%) and pharmacovigilance (3.6%). According to the pilot policy workshop, other criteria apart from price need to be strengthened in the tendering process. The introduction of additional criteria for OPP procurement in an MCDA framework creates incentives for manufacturers to invest into improved manufacturing standards, equivalence proof, product quality, reliability of supply or even additional real-world data collection, which ultimately may result in more health gain for the society.

24 October 2016 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
AYAlfi Yasmina
Alfi Yasmina
ABAnthonius de Boer
Anthonius de Boer
VDVera H.M. Deneer
Vera H.M. Deneer
PSPatrick C. Souverein
Patrick C. Souverein
OKOlaf H. Klungel
Olaf H. Klungel
Aims: The aims of the present study were to assess antiplatelet drug use patterns after a first myocardial infarction (MI) and to evaluate the determinants of antiplatelet nonpersistence.Methods: The present study was conducted in 4690 patients from the Utrecht Cardiovascular Pharmacogenetics cohort with a first MI between 1986 and 2010, who were followed for a maximum of 10 years. Medication use and event diagnosis were obtained from the Dutch PHARMO Record Linkage System. Antiplatelet drug users were classified as persistent users (gap between prescriptions ≤90 days), nonpersistent users (>90‐day gap and no refills), and restarters (a new prescription after a >90‐day gap). The association between potential determinants and antiplatelet nonpersistence was analysed using Cox regression.Results: The proportions of persistent users decreased from 84.0% at the 1‐year follow‐up to 32.8% at 10 years for any antiplatelet drug, and 77.3% to 27.5% for aspirin; and 39.0% to 6.4% for clopidogrel at 6 years. Most nonpersistent users restarted antiplatelet drugs later, leading to 89.3% overall antiplatelet drug users at 10 years after MI. Diabetes (hazard ratio [HR] 0.44; 0.32–0.60), hypertension (HR 0.77; 0.60–0.99), hypercholesterolaemia (HR 0.49; 0.39–0.62) and more recent MI diagnosis period (2003–2007: HR 0.69, 0.61–0.79; 2008–2010: HR 0.38, 0.19–0.77, compared to ≤ 2002 period) lowered the risk of antiplatelet nonpersistence, while vitamin K antagonist (VKA) comedication (HR 18.97; 16.91–21.28) increased this risk.Conclusions: A large proportion of patients with a first MI still used antiplatelet drugs after 10 years. The frequent discontinuations during this time frame are expected to reduce the effectiveness of antiplatelet drugs as secondary prevention of cardiovascular diseases. Diabetes, hypertension, hypercholesterolaemia, VKA comedication and MI diagnosis period were determinants of antiplatelet nonpersistence.

13 March 2014 in Pharmacogenomics
Verified
Journal Article
Closed access
AYAlfi Yasmina
Alfi Yasmina
ABAnthonius de Boer
Anthonius de Boer
OKOlaf H Klungel
Olaf H Klungel
VDVera Hm Deneer
Vera Hm Deneer
Pharmacogenomics has been implicated in the response variability of antiplatelet drugs in coronary artery disease (CAD), particularly for aspirin and clopidogrel. A large number of studies and several meta-analyses have been published on this topic, but until recently, there have been no clear conclusions and no definite guidelines on the clinical use of pharmacogenetic testing before prescribing antiplatelet drugs for CAD. In this review, the available evidence is summarized. The most consistent results are on clopidogrel, where CYP2C19 loss-of-function alleles are associated with stent thrombosis events. We recommend to genotype for CYP2C19 loss-of-function alleles in patients with CAD who are to undergo percutaneous coronary intervention and stenting, and to adjust the antiplatelet treatment based on the genotyping results.

27 May 2014 in Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
AYAlfi Yasmina
Alfi Yasmina
VDV. H. M. Deneer
V. H. M. Deneer
Anke H. Maitland-van der ZeeAnke H. Maitland-van der Zee
Anke H. Maitland-van der Zee
VSVictoria van Staa
Victoria van Staa
ABA. de Boer
A. de Boer
OKO.H. Klungel
O.H. Klungel

11 September 2020 in Genes
Verified
Journal Article
Open access
PDF file
TBThomas Bergmeijer
Thomas Bergmeijer
AYAlfi Yasmina
Alfi Yasmina
GVGerrit J. A. Vos
Gerrit J. A. Vos
PJPaul W. A. Janssen
Paul W. A. Janssen
CHChristian M. Hackeng
Christian M. Hackeng
VDVera H.M. Deneer
Vera H.M. Deneer
This study aims to determine whether genetic variants that influence CYP3A4 expression are associated with platelet reactivity in clopidogrel-treated patients undergoing elective percutaneous coronary intervention (PCI), and to evaluate the influence of statin/fibrate co-medication on these associations. A study cohort was used containing 1124 consecutive elective PCI patients in whom CYP3A4*22 and PPAR-α (G209A and A208G) SNPs were genotyped and the VerifyNow P2Y12 platelet reactivity test was performed. Minor allele frequencies were 0.4% for CYP3A4*22/*22, 6.8% for PPAR-α G209A AA, and 7.0% for PPAR-α A208G GG. CYP3A4*22 was not associated with platelet reactivity. The PPAR-α genetic variants were significantly associated with platelet reactivity (G209A AA: −24.6 PRU [−44.7, −4.6], p = 0.016; A208G GG: −24.6 PRU [−44.3, −4.8], p = 0.015). Validation of these PPAR-α results in two external cohorts, containing 716 and 882 patients, respectively, showed the same direction of effect, although not statistically significant. Subsequently, meta-analysis of all three cohorts showed statistical significance of both variants in statin/fibrate users (p = 0.04 for PPAR-a G209A and p = 0.03 for A208G), with no difference in statin/fibrate non-users. In conclusion, PPAR-α G209A and A208G were associated with lower platelet reactivity in patients undergoing elective PCI who were treated with clopidogrel and statin/fibrate co-medication. Further research is necessary to confirm these findings.

14 February 2023 in Jurnal Berkala Ilmiah Sains dan Terapan Kimia
Verified
Journal Article
Open access
PDF file
IIIsnaini Isnaini
Isnaini Isnaini
RARosinta Dewi Achmadiyah
Rosinta Dewi Achmadiyah
GAGelvia Awaeh
Gelvia Awaeh
HKHusnul Khatimah
Husnul Khatimah
AYAlfi Yasmina
Alfi Yasmina
Melaleuca cajuputi subsp. Cumingiana [Turcz.] Barlow (M. cajuputi) is a plant that is easily found in Banjarmasin. M. cajuputi contains phytochemical compounds in the form of polyphenols including flavonoids, quinons, saponins, and alkaloids that are thought to have antioxidant and antiproliferation activities. The aim of this research was to find out analyze antioxidant and antiproliferation activity of M. cajuputi fruit methanol extract. The antioxidant activity was tested using the DPPH method. The activities were observed in IC50 and were measured using the UV-VIS spectrophotometer at a wavelength of 517 nm. To test the antiproliferation, true experimental with post-test was applied in this research. Animal used in this study were 30 mature zebras (length > 2.5 cm) which were grouped into 4, namely the negative control group (DMSO 0.05%), the methanol extract group of M. cajuputi with concentrations of 18.5 ppm, 37 ppm and 74 ppm. The bound variable in this study was antiproliferation activity in the tail of an amputated fish. Data analysis was measured by one-way ANOVA and Post-Hoc Tukey HSD tests. Phytochemical results obtained the presence of phenol compounds, cuinons, flavonoids, alkaloids, saponins, tannins, steroids and terpenoids. Methanol extract of Melaleuca cajuputi subsp Cumingiana [Turcz.] Barlow fruit was at IC50 of 15.50 ppm (95% CI 8.31- 32.72). The antiproliferation activity of zebrafish tails increased in the administration of fruit extract Melaleuca cajuputi subsp. Cumingiana [Turcz.] Barlow in consentration of 74 ppm (p<0.05), both on day 4 and day 8 of measurement when compared to negative controls. It can be concluded that methanol extract of Melaleuca cajuputi subsp Cumingiana [Turcz.] Barlow fruit has antiproliferative activity against the growth of amputated zebrafish tails.